Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T +/- pTVG-HP DNA Vaccine in mCRPC
NCT01706458Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2013
- Primary completion
- Jun 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pTVG-HP plasmid DNA vaccine in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Wisconsin–Madison. Started May 2013; status: completed.
02
Drugs
pTVG-HP plasmid DNA vaccine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01706458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01706458.